H2O2-Responsive Nanoparticles for Glucose-Controlled Insulin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current closed-loop insulin delivery systems for diabetes management face challenges in accuracy, reliability, and biocompatibility due to the need for frequent monitoring and subcutaneous implantation, with existing glucose-responsive materials limited by pH sensitivity and biocompatibility concerns.
Innovation Solution
Development of nanoparticles comprising a copolymer with a polyethylene glycol polymer, a polyhydroxylated polymer, and a peroxide-sensitive pendant group, encapsulating a glucose-responsive agent like glucose oxidase and a therapeutic agent like insulin, which releases insulin in response to hyperglycemic levels by scavenging hydrogen peroxide and altering solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucose-responsive materials incorporate glucose oxidase for closed-loop insulin release, then insulin delivery responsiveness is improved, but biocompatibility deteriorates due to pH sensitivity and hydrogen peroxide accumulation
Solution Approach 1:
The patent converts the harmful hydrogen peroxide byproduct of glucose oxidase activity into a beneficial trigger signal. The H2O2-responsive nanoparticle system detects accumulated H2O2 levels as a signal of hyperglycemia and uses it to trigger insulin release, thereby transforming a harmful substance into a useful signaling molecule for closed-loop control
Solution Approach 2:
The patent introduces H2O2 as an intermediary mediator between glucose metabolism and insulin release. Instead of direct glucose-pH-material interaction, the system uses H2O2 as a intermediate signal that connects glucose oxidase activity to the nanoparticle disassembly and insulin release mechanism
2Reliability
If subcutaneous implantation of cannula is used for continuous insulin infusion, then closed-loop control reliability is improved, but ease of operation deteriorates due to tubing requirements and biofouling
Solution Approach 1:
The patent extracts and eliminates the complex tubing and cannula system from the insulin delivery mechanism. By using injectable nanoparticles that self-assemble and respond autonomously to glucose levels, the system removes the need for continuous physical connections, pumps, and external monitoring equipment
Solution Approach 2:
The nanoparticle system performs self-service by autonomously sensing glucose levels through embedded glucose oxidase and automatically releasing insulin in response to H2O2 signals, eliminating the need for external pumps, tubing, and manual intervention required by traditional insulin pumps
3Measurement precision
If frequent subcutaneous injections of insulin are administered to maintain normoglycemia, then glucose control accuracy is improved, but ease of operation deteriorates due to pain and patient burden
Solution Approach 1:
The patent establishes continuous action by formulating insulin within nanoparticles that remain active in circulation and continuously monitor glucose levels through embedded glucose oxidase. The system provides uninterrupted glucose-responsive insulin release rather than discrete injection events
Solution Approach 2:
The nanoparticle system performs self-service by autonomously sensing glucose levels and triggering insulin release without requiring patient intervention. The embedded glucose oxidase continuously monitors glucose and the H2O2-responsive mechanism automatically releases insulin when needed, eliminating the need for frequent manual injections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle system provides rapid, controlled insulin release in response to hyperglycemic conditions, maintaining normoglycemia while avoiding hypoglycemia and reducing tissue damage, with excellent biocompatibility and ease of use.
Implementation Method 1
The matrix typically employs glucose-responsive moieties such as glucose oxidase (GOx), phenylboronic acid (PBA), or glucose binding proteins (GBP) to regulate the release rate of the pre-loaded insulin by polymer degradation, structure switch or glucose binding competition.
Implementation Method 2
a copolymer comprising a polyethylene glycol polymer, a polyhydroxylated polymer, and a peroxide-sensitive pendant group
Implementation Method 3
the detaching step increases solubility of the copolymer in water. In some embodiments, the increased water solubility of the copolymer dissociates the copolymer from the therapeutic agent, thereby releasing the therapeutic agent from the nanoparticle.
Data Source
AI summary
Disclosed herein is a nanoparticle comprising a copolymer comprising a polyethylene glycol polymer, a polyhydroxylated polymer, and a peroxide-sensitive pendant group; a glucose-responsive agent; and a therapeutic agent; wherein the copolymer encapsulates the glucose-responsive agent and the therapeutic agent. Also disclosed herein is a method of delivering a therapeutic agent to a subject comprising administering to the subject a nanoparticle comprising a copolymer comprising a polyethylene glycol polymer, a polyhydroxylated polymer, and a peroxide-sensitive pendant group; a glucose-responsive agent; and a therapeutic agent; wherein the copolymer encapsulates the glucose-responsive agent and the therapeutic agent; and releasing the therapeutic agent from the nanoparticle in the presence of hyperglycemic levels of glucose. In some embodiments, the glucose-responsive agent produces a peroxide when exposed to hyperglycemic levels of glucose, thereby triggering disassembly of the nanoparticle and release of encapsulated therapeutic agent.